Ret Proto-Oncogene Antikörper (Extracellular, N-Term)

Produktnummer ABIN7886748

Der Kaninchen Polyklonal anti-Ret Proto-Oncogene Antikörper wird verwendet zum Nachweis von Ret Proto-Oncogene in Proben von Human. Er wurde validiert für WB, IHC, IF, FACS, LCI und IC.

Kurzübersicht für Ret Proto-Oncogene Antikörper (Extracellular, N-Term) (ABIN7886748)

Target: Ret Proto-Oncogene (RET)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS), Live Cell Imaging (LCI), Immunochromatography (IC)

Produktdetails anti-Ret Proto-Oncogene Antikörper

Bindungsspezifität: AA 541-553, Extracellular, N-Term

Verwendungszweck: A Rabbit Polyclonal Antibody to Ret Receptor

Kreuzreaktivität: Human, Maus, Ratte

Kreuzreaktivität (Details): This antibody will recognize the intact Ret receptor and the cleaved Ret extracellular cell-membrane anchored fragment. It won't recognize the cleaved Ret kinase fragment.

Homologie: Mouse - identical, rat - 12,13 amino acid residues identical

Produktmerkmale: Anti-Ret (extracellular) Antibody is directed against an extracellular epitope of human Ret. Anti-Ret (extracellular) Antibody ( (ABIN7043600, ABIN7044783 and ABIN7044784) can be used in western blot, indirect flow cytometry, immunohistochemistry and immunocytochemistry applications and has been designed to recognize Ret from rat, mouse and human samples.

Aufreinigung: Affinity purified on immobilized antigen.

Immunogen: CEWRQGDGKGITR, corresponding to amino acid residues 541-553 of human Ret

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

WB: 1:200

FC: 5 μg per reaction

ICC: 1:25

IHC: 1:50

IP: The optimal concentration should be determined by the user

Kommentare:

Cited Application: ICC

Negative Control: (ABIN7236725)

Blocking Peptide: (ABIN7236725)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Konzentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Details zu Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Andere Bezeichnung: RET

Hintergrund:

Synonyms: Proto-oncogene tyrosine-protein kinase receptor Ret, Proto-oncogene c-Ret, Cadherin family member 12, CDHF12

Description: The RET proto-oncogene on human chromosome 10q11.2, encodes a receptor tyrosine kinase (RTK) activated by members of the glial cell line-derived neurotrophic factor (GDNF) ligand family (GDNF, neurturin, artemin, and persephin) in conjunction with a ligand-specific coreceptor (GFRα1-4)1. RET belongs to the cadherin superfamily, and it has been suggested that the ret gene is the result of a recombination between a gene encoding a tyrosine kinase receptor and a gene encoding an ancestral cadherin at an early stage of evolution2. The extracellular domain of RET comprises, as observed for other tyrosine kinase receptors, a cysteine-rich domain, but also four cadherin-like domains3.RET signaling is crucial for the development of the enteric nervous system. RET also regulates the development of sympathetic, parasympathetic, motor, and sensory neurons, and is necessary for the postnatal maintenance of dopaminergic neurons. Outside the nervous system, RET is crucial for development of the kidney and plays a key role in spermatogenesis3.RET has attracted considerable clinical interest because of the range of mutations found in diverse conditions that include Hirschsprung disease and a variety of cancers involving the thyroid gland. RET-related cancers with thyroid involvement include sporadic and familial medullary thyroid carcinoma (MTC), multiple endocrine neoplasia 2 (MEN2) syndromes MEN2A and MEN2B, and papillary thyroid carcinoma (PTC)4.

Gen-ID: 5979

NCBI Accession: NM_020975

UniProt: P07949

Pathways: RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation